Precision Neuroscience has shifted focus from Elon Musk-owned Neuralink, offering implanted technology that helps patients with neurological disorders. Precision Neuroscience Co-Founder & CEO Michael Mager joins Yahoo Finance’s Yasmin Khorram to explore what lies ahead for the brain-computer interface company.

Yahoo Finance Invest 2024 brings to life our promise to the investing community: Behind every great investor is Yahoo Finance. 2024 brought on numerous forces that have impacted our economy and markets in unprecedented ways. AI boom. Shifting Fed policy moves. And when we gather this fall, the outcome of a heated US presidential election will be front and center for investors globally. The combination of these macroeconomic trends, tech breakthroughs and a new administration will bring a lot of unanswered questions for investors. Join Yahoo Finance Invest to hear from executives from some of the world’s largest corporations, thought leaders, and policy makers through conversations moderated by Yahoo Finance’s editorial team.

Get more Invest 2024 at https://finance.yahoo.com/videos/event/invest/

00:00 - Michael Mager joins Invest

01:50 - How AI helps paralysis patients

04:35 - How Precision used semiconductor manufacturing techniques for biomedical purposes

06:23 - Difference between Precision Neuroscience and Neuralink

08:51 - Precision ’s minimally invasive approach

10:08 - How Precision’s chip reads the human brain

11:21 - Safeguarding against data security and privacy issue of brain-computer interfaces

13:38 - Why Precision Neuroscience’s technology could extend beyond treating paralysis 

18:13 - Precision’s regulatory roadmap 

20:57 - Precision’s future under a Trump administration that could include RFK and Elon Musk

24:31 - Precision Neuroscience’s potential IPO

Thoughts? Questions? Fan mail? Email us at [email protected].